Vessi Medical

Vessi Medical takes a new approach in the treatment of superficial bladder cancer. The Company uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue.

Vessi Medical’s Novel Approach

Vessi Medical’s minimally invasive non-muscle-invasive bladder cancer (NMIBC) solution provides an office-based therapeutic alternative to surgery. The Company uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue.

The Vessi Medical system consists of a standalone console and a disposable catheter that is inserted into the bladder similar to existing intravesical (inside the bladder) techniques.

Advantages

  • Proven high efficacy rate (for surface lesions)
  • Reduced complications and side effects
  • Reduces risk of dispersed cancer cells
  • No muscle bladder damage
  • Inexpensive

Currently, surface cryotherapy is used extensively in many applications, and it has been known to be highly effective in destroying surface lesions.

The Vessi Medical Opportunity

The market seeks an effective treatment for superficial bladder cancer that offers reduced recurrence rates, reduced side effects, improved patient outcomes, and lower health care costs.

Status

Founded: Joined Trendlines Medical July 2017
Stage: Technology development
Investor: The Trendlines Group
IP: National phase and PCT

The Team

VessiMed CEO Eyal Kochavi

Vessi Medical CEO Eyal Kochavi takes a break from the American Urological Association Annual Meeting in San Francisco, 18-21 May.

  • Eyal Kochavi, CEO and Founder: 14 years’ experience in bringing medical device products to the market, in particular in the cryotherapy and urology fields; prior positions include VP R&D and business development, project manager, and director R&D; MBA and MSc (cum laude), Technion-Israel Institute of Technology
  • Moti Simchon, Cryogenics Adviser: 45 years’ experience in pneumatics, fine mechanics, and cryogenics; proven out-of-the-box thinker
  • Prof. Gilad E. Amiel, Scientific Adviser: Chairman, Department of Urology, Rambam Health Care Campus, Israel; adjunct Associate Professor of Urology, Baylor College, Houston, Texas; former President of the American Association for Cancer Education (AACE); member of the American Urological Association (AUA) and several other professional organizations
  • Doron Birger, Business Advisor: Former President and CEO, Elron; former Chairman, Given Imaging; chairman and board member of numerous medical device companies

Trendlines’ directors: Nitza Kardish, Steve Rhodes 

Background & Market

Non-muscle-invasive bladder cancer (NMIBC), also known as superficial bladder cancer, is found on the surface of the inside lining of the bladder, and accounts for ~75% of new patients with bladder cancer. In cases of high-risk superficial bladder cancer, treatment involves intravesical therapy in which an immunotherapy or chemotherapy drug is inserted directly into the bladder via a catheter. These therapy modalities cause severe side effects and have limited outcomes. Unfortunately, due to high recurrence rates, many patients undergo bladder removal.

Reports state that bladder cancer has the highest cost per patient of all cancers, and that 43% of all bladder removals begin with superficial cancer (European Association of Urology. 2012. Guidelines on Bladder Cancer Muscle-invasive and Metastatic.)

NMIBC affects 2 million people globally with 300,000 new cases reported yearly (Turk J Urol. March 2016 ).

Vessi Medical estimates its immediate U.S. addressable market at $400 million per year with a global market potential at over $1 billion annually and estimates its global market potential at over $1 billion annually.

Vessi Medical logo
Cryotherapy for superficial bladder cancer

Media


See the Vessi Medical system.

Contact

Eyal Kochavi, CEO
+972.52.523.5454
eyal@vessimed.com

Font Resize
Contrast